Literature DB >> 18618240

Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.

Doris Auer1, Daniel Reimer, Verena Porto, Martina Fleischer, Julia Roessler, Annemarie Wiedemair, Christian Marth, Elisabeth Müller-Holzner, Günter Daxenbichler, Alain G Zeimet.   

Abstract

This study analyzes the relationship between coxsackie-adenovirus receptor (CAR) expression (transmembrane and soluble isoforms) and hormone sensitivity in 95 breast cancers. Furthermore, prognostic significance of the expression of the various CAR isoforms was investigated. In addition, inducibility of CAR expression by estradiol and tamoxifen was assessed in various breast cancer cell lines. Expression of transmembrane CAR (hCAR) highly correlated with estrogen receptivity, but was independent of the expression of progesterone receptor (PR). Furthermore, hCAR expression was significantly higher in tumors with low-grade malignancy. However, no relationship between hCAR expression and tumor size, lymph node status, or survival was revealed. In the hormone receptor-positive breast cancer cell line T47-D expression of hCAR and its soluble isoforms was increased by treatment with estradiol and tamoxifen. In contrast, no induction of either CAR isoform was achieved in receptor-negative cell lines. Furthermore, enhancement of hCAR expression was significantly greater when cells were treated with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) than when treated with estradiol or tamoxifen. Moreover, sensitivity to TSA induction of hCAR was considerably greater in receptor-positive than in receptor-negative cell lines. No additive effect on CAR expression was found when TSA was combined with either estradiol or tamoxifen. In conclusion, the so far undescribed association between estrogen receptivity and the expression of hCAR in breast cancer seems to not only reflect a phenotype of low malignancy, but expression of hCAR may also be directly influenced by ER-specific ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18618240     DOI: 10.1007/s10549-008-0108-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Junfen Ma; Nan Li; Jimin Zhao; Jing Lu; Yanqiu Ma; Qinghua Zhu; Ziming Dong; Kangdong Liu; Liang Ming
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

2.  Novel splice variant CAR 4/6 of the coxsackie adenovirus receptor is differentially expressed in cervical carcinogenesis.

Authors:  Marit Dietel; Norman Häfner; Lars Jansen; Matthias Dürst; Ingo B Runnebaum
Journal:  J Mol Med (Berl)       Date:  2011-03-23       Impact factor: 4.599

Review 3.  Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis.

Authors:  Astrid O Leech; Rodrigo G B Cruz; Arnold D K Hill; Ann M Hopkins
Journal:  Ann Transl Med       Date:  2015-08

4.  Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis.

Authors:  M Reeh; M Bockhorn; D Görgens; M Vieth; T Hoffmann; R Simon; J R Izbicki; G Sauter; U Schumacher; M Anders
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

5.  Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.

Authors:  Junji Uchino; David T Curiel; Hideyo Ugai
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  Restructuring the ONYX-015 adenovirus by using spike protein genes from SARS-CoV-2 and MERS-CoV: Possible implications in breast cancer treatment.

Authors:  Hamendra Singh Parmar; Aakruti Nayak; Shreya Kataria; Versha Tripathi; Pooja Jaiswal; Pramod Kumar Gavel; Hem Chandra Jha; Shivani Bhagwat; Amit Kumar Dixit; Vladimir Lukashevich; Apurba Kumar Das; Rajesh Sharma
Journal:  Med Hypotheses       Date:  2022-01-04       Impact factor: 1.538

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.